When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Medicare Coverage for COPD Inhalers - AOL

   www.aol.com/medicare-coverage-copd-inhalers...

   If you have chronic obstructive pulmonary disease (COPD), an inhaler can help relax your airway or reduce inflammation, making it easier to breathe. You can use several types of inhalers for COPD ...

3. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

4. Ipratropium bromide - Wikipedia

   en.wikipedia.org/wiki/Ipratropium_bromide

   [3] [4] It is used to treat the symptoms of chronic obstructive pulmonary disease (COPD) and asthma. [3] It is used by inhaler or nebulizer. [3] Onset of action is typically within 15 to 30 minutes and lasts for three to five hours. [3] The nasal spray prevents the glands in the nose from producing large amounts of fluid.

5. Pulmonary drug delivery - Wikipedia

   en.wikipedia.org/wiki/Pulmonary_drug_delivery

   Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...

6. Dry-powder inhaler - Wikipedia

   en.wikipedia.org/wiki/Dry-powder_inhaler

   A dry-powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma , bronchitis , emphysema and COPD although DPIs (such as inhalable insulin ) have also been used in the treatment of diabetes mellitus .

7. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

   www.aol.com/news/astrazeneca-cap-us-pocket-costs...

   (Reuters) -AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, starting June, following a similar move by rival ...